BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2008

View Archived Issues

Acucela doses first subject in phase I age-related macular degeneration trial

Read More

Genetic cause found for X-linked rare inherited disorder causing epilepsy and mental retardation

Read More

Gene therapy slows neurological decline in children with neuronal ceroid lipofuscinosis

Read More

Protalix to commence open-label extension study for its phase III prGCD trial

Read More

Addex commences phase I interaction study with new ADX-10059 formulation

Read More

MediGene to focus R&D activities on oncology and immunology fields

Read More

GSK exercises right to AM-803 FLAP inhibitor under agreement with Amira

Read More

Santen files Japanese manufacturing and marketing approval applications for DE-089

Read More

Santen enters agreement in Japan and Asia with MacuSight for sirolimus

Read More

Addrenex completes enrollment in U.S. phase III clinical trial of Clonicel in ADHD

Read More

Avexa enters collaboration with TargetDrug for novel lead inhibitors of HCV replication

Read More

Nabi receives a USD 2.5 million milestone payment from Fresenius for CARE-2 study

Read More

Callisto commences phase I trial for constipation and IBD candidate SP-304

Read More

NIAID initiates phase I safety study of Avant's oral ETEC-Cholera vaccine

Read More

Astra Zeneca reports on novel GABA-B agonist candidate for reflux treatment

Read More

Positive first-in-human results for novel multi-CDK inhibitor PHA-848125

Read More

Kyowa Hakko and Kyorin terminate collaborative marketing agreement for Allelock

Read More

Tripep reports positive results from ongoing study of ChronVac-C HCV therapeutic vaccine

Read More

Novartis acquires Protez and North American and European rights to PZ-601 antibiotic

Read More

CHMP issues positive opinion for antibacterial agent Doribax

Read More

Emergent BioSolutions initiates phase II trial for oral typhoid vaccine candidate

Read More

Pharmacopeia identifies new lead compound for advancement under collaboration with GSK

Read More

Recent Purdue Pharma and Neuro Therapeutics patents describe novel analgesic agents

Read More

Recent Biostatin patent discloses novel agents for treating chronic wounds

Read More

New treatment options for gastrointestinal disorders described in recent patents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing